Q2 EPS Estimate for Esperion Therapeutics Cut by Analyst

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities research analysts at HC Wainwright lowered their Q2 2025 earnings per share estimates for Esperion Therapeutics in a research note issued to investors on Tuesday, May 6th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn ($0.19) per share for the quarter, down from their prior forecast of ($0.12). HC Wainwright currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics' Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.17 EPS.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). The firm had revenue of $65.00 million during the quarter, compared to the consensus estimate of $54.97 million.

A number of other equities analysts also recently commented on ESPR. JMP Securities restated a "market outperform" rating and issued a $4.00 price objective (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Needham & Company LLC decreased their price objective on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, The Goldman Sachs Group cut their target price on Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $6.25.

Esperion Therapeutics Stock Performance

Shares of NASDAQ:ESPR traded down $0.05 during midday trading on Friday, hitting $0.73. 6,580,758 shares of the stock were exchanged, compared to its average volume of 5,525,917. Esperion Therapeutics has a 52-week low of $0.72 and a 52-week high of $3.94. The business's fifty day simple moving average is $1.21 and its two-hundred day simple moving average is $1.86. The company has a market capitalization of $144.85 million, a PE ratio of -1.14 and a beta of 0.75.

Institutional Investors Weigh In On Esperion Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ESPR. Summit Financial LLC increased its position in shares of Esperion Therapeutics by 18.2% during the fourth quarter. Summit Financial LLC now owns 46,528 shares of the biopharmaceutical company's stock valued at $102,000 after purchasing an additional 7,150 shares during the period. Foundations Investment Advisors LLC increased its holdings in Esperion Therapeutics by 48.6% in the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 9,872 shares during the period. Private Advisor Group LLC raised its stake in shares of Esperion Therapeutics by 33.2% in the 1st quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company's stock valued at $58,000 after buying an additional 10,000 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Esperion Therapeutics by 15.5% during the 4th quarter. Invesco Ltd. now owns 97,833 shares of the biopharmaceutical company's stock worth $215,000 after acquiring an additional 13,101 shares during the period. Finally, Two Sigma Advisers LP boosted its position in shares of Esperion Therapeutics by 0.4% during the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company's stock valued at $7,956,000 after acquiring an additional 16,100 shares in the last quarter. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.